Prognosis of recurrent non‑small cell lung cancer following complete resection

Sasaki,Hidefumi; Suzuki,Ayumi; Tatematsu,Tsutomu; Shitara,Masayuki; Hikosaka,Yu; Okuda,Katsuhiro; Moriyama,Satoru; Yano,Motoki; Fujii,Yoshitaka

doi:10.3892/ol.2014.1861

Prognosis of recurrent non‑small cell lung cancer following complete resection

Authors:
- Hidefumi Sasaki
- Ayumi Suzuki
- Tsutomu Tatematsu
- Masayuki Shitara
- Yu Hikosaka
- Katsuhiro Okuda
- Satoru Moriyama
- Motoki Yano
- Yoshitaka Fujii
View Affiliations

Affiliations: Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467‑8601, Japan
Published online on: February 7, 2014 https://doi.org/10.3892/ol.2014.1861
Pages: 1300-1304

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prognosis following recurrence subsequent to complete resection of non‑small‑cell lung cancer (NSCLC) is considered a multifactorial process dependent on clinicopathological, biological and treatment characteristics. Gefitinib was approved for lung cancer treatment in Japan in 2002. The aim of the current study was to quantify the prognostic effects of these characteristics on post‑recurrence prognosis. In total, 127 NSCLC patients were analyzed who underwent complete resection and subsequently had recurrent cancer. The correlation between characteristics of the initial and recurrent disease with post‑recurrence prognosis was investigated. The factors clearly associated with post‑recurrence prognosis using Cox proportional hazards models were age at recurrence (those <65 years of age typically had better prognoses) and interval between initial resection and recurrence (intervals of <1 year accompanied a worse prognosis). Epidermal growth factor receptor (EGFR) mutant patients treated with EGFR tyrosine kinase inhibitors (TKIs), exhibited the longest median survival following recurrence (37.4 months) in the sample. Treatment, particularly EGFR TKIs for recurrent NSCLC, was observed to significantly prolong survival. The results of the study highlight that various treatment modalities according to the clinical background of the patient should be considered in patients with postoperative recurrent NSCLC.

View Figures

View References

1	Martini N, Bains MS, Burt ME, et al: Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 109:120–129. 1995. View Article : Google Scholar : PubMed/NCBI
2	al-Kattan K, Sepsas E, Fountain SW and Townsend ER: Disease recurrence after resection for stage I lung cancer. Eur J Cardiothorac Surg. 12:380–384. 1997. View Article : Google Scholar : PubMed/NCBI
3	Yoshino I, Yohena T, Kitajima M, et al: Survival of non-small cell lung cancer patients with postoperative recurrence at distant organs. Ann Thorac Cardiovasc Surg. 7:204–209. 2001.
4	Martin J, Ginsberg RJ, Venkatraman ES, et al: Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol. 20:1989–1995. 2002. View Article : Google Scholar : PubMed/NCBI
5	Williams BA, Sugimura H, Endo C, et al: Predicting post-recurrence survival among completely resected nonsmall-cell lung cancer patients. Ann Thorac Surg. 81:1021–1027. 2006. View Article : Google Scholar : PubMed/NCBI
6	Sugimura H, Nichols FC, Yang P, et al: Survival after recurrent non-small-cell lung cancer after complete pulmonary resection. Ann Thorac Surg. 83:409–418. 2007. View Article : Google Scholar : PubMed/NCBI
7	Hung JJ, Hsu WH, Hsieh CC, et al: Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax. 64:192–196. 2009. View Article : Google Scholar : PubMed/NCBI
8	Shimada Y, Saji H, Yoshida K, et al: Prognostic factors and the significance of treatment after recurrence in completely resected stage I non-small cell lung cancer. Chest. 143:1626–1634. 2013.PubMed/NCBI
9	Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
10	Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
11	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
12	Paz-Ares L, de Marinis F, Dediu M, et al: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 13:247–255. 2012.
13	Reck M, von Pawel J, Zatloukal P, et al: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung: results from a randomised phase III trial (AVAiL). Ann Oncol. 21:1804–1809. 2010. View Article : Google Scholar
14	Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
15	Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
16	Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
17	Sasaki H, Endo K, Mizuno K, et al: EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer. Lung Cancer. 51:135–136. 2006. View Article : Google Scholar : PubMed/NCBI
18	Fukuoka M, Wu YL, Thongprasert S, et al: Biomarker analyses and first overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 29:2866–2874. 2011. View Article : Google Scholar
19	The Japan Lung Cancer Society. The General Rule for Clinical and Pathological Record of Lung Cancer. 7th edition. Kanehara Shuppan; Tokyo, Japan: pp. 1–234. 2010
20	Sasaki H, Endo K, Konishi A, et al: EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res. 11:2924–2929. 2005. View Article : Google Scholar : PubMed/NCBI
21	Sasaki H, Shimizu S, Endo K, et al: EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer. 118:180–184. 2006. View Article : Google Scholar : PubMed/NCBI
22	Ichinose Y, Yano T, Yokoyama H, et al: Postrecurrent survival of patients with non-small-cell lung cancer undergoing a complete resection. J Thorac Cardiovasc Surg. 108:158–161. 1994.PubMed/NCBI
23	Walsh GL, O’Connor M, Willis KM, et al: Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg. 60:1563–1572. 1995. View Article : Google Scholar : PubMed/NCBI
24	Ichinose Y, Kato H, Koike T, et al: Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer. 34:29–36. 2001. View Article : Google Scholar
25	Mitsudomi T, Nishioka K, Maruyama R, et al: Kinetic analysis of recurrence and survival after potentially curative resection of nonsmall cell lung cancer. J Surg Oncol. 63:159–165. 1996. View Article : Google Scholar : PubMed/NCBI
26	Yano T, Hara N, Ichinose Y, et al: Local recurrence after complete resection for non-small-cell carcinoma of the lung. Significance of local control by radition treatment. J Thorac Cardiovasc Surg. 107:8–12. 1994.
27	Emami B, Graham MV, Deedy M, Shapiro S and Kucik N: Radiation therapy for intrathoracic recurrence of non-small cell lung cancer. Am J Clin Oncol. 20:46–50. 1997. View Article : Google Scholar : PubMed/NCBI
28	Sequist LV, Joshi VA, Jänne PA, et al: Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist. 12:90–98. 2007. View Article : Google Scholar : PubMed/NCBI
29	Yang CH, Yu CJ, Shih JY, et al: Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol. 26:2745–2753. 2008. View Article : Google Scholar
30	Kosaka T, Yatabe Y, Endo H, et al: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res. 12:5764–5769. 2006. View Article : Google Scholar : PubMed/NCBI
31	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar